Barrett Asset Management LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 1.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 281,759 shares of the company’s stock after acquiring an additional 3,885 shares during the quarter. Johnson & Johnson accounts for approximately 2.8% of Barrett Asset Management LLC’s investment portfolio, making the stock its 4th largest holding. Barrett Asset Management LLC’s holdings in Johnson & Johnson were worth $37,274,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. OLD Point Trust & Financial Services N A raised its holdings in shares of Johnson & Johnson by 2.2% in the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock valued at $8,113,000 after acquiring an additional 1,321 shares in the last quarter. Lynch & Associates IN raised its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares in the last quarter. Welch & Forbes LLC raised its holdings in shares of Johnson & Johnson by 0.9% in the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after acquiring an additional 6,730 shares in the last quarter. Oakbrook Investments LLC raised its holdings in shares of Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in Johnson & Johnson by 0.5% in the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after purchasing an additional 3,533 shares in the last quarter. Hedge funds and other institutional investors own 65.93% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $138.00 on Friday. The company has a market capitalization of $373,080.00, a P/E ratio of 19.54, a P/E/G ratio of 2.83 and a beta of 0.82. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $144.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.68 earnings per share. equities analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.43%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/18/johnson-johnson-jnj-is-barrett-asset-management-llcs-4th-largest-position.html.

JNJ has been the subject of a number of recent research reports. Goldman Sachs Group, Inc. (The) downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. BMO Capital Markets reiterated a “buy” rating and issued a $145.00 target price on shares of Johnson & Johnson in a report on Friday, September 1st. Alembic Global Advisors downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Finally, Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price for the company in a report on Monday, October 30th. Four analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $143.70.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.